Encouraging results from ProQR USH2A clinical trial
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
Search results
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Stephen Goulden MBE attended the first British Retinitis Pigmentosa Society (BRPS) meeting in 1977. He describes his involvement with the charity and with inherited sight loss as follows:
Join Research Development Manager, Kate Arkell as she speaks to our latest research grantees about their projects.
Retina UK invites applications for funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease. We are particularly keen to receive proposals with demonstrable translational potential.
Sanaregen Vision Therapeutics has received FDA clearance to begin a first-in-human clinical trial of SVT-001, an investigational cell therapy for Familial Drusen, a rare inherited retinal disease that currently has no approved treatment.
Dr Rachel Taylor is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team at the University of Manchester.
Eye2Gene: new publication describes how AI can predict genetic diagnosis from retinal scans
Wednesday 2 December 2026, 7.00pm - 8.00pm - via Zoom - Please come and join facilitators Cindy & Jane for our latest meeting where we are delighted to welcome our guest speaker and author Mark Billingham as well as reviewing our current book choice.